title: Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
abstract: OBJECTIVE
  Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes.
  
  
  METHODS
  Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period.
  
  
  RESULTS
  High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction.
  
  
  CONCLUSIONS
  Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.
authors.affiliation: Corresponding author: Kristina I. Rother, kristina.rother@nih.gov.
authors.forename: Gayatri
authors.initials: G
authors.lastname: Sarkar
authors.forename: May
authors.initials: M
authors.lastname: Alattar
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Brown
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Quon
authors.forename: David M
authors.initials: DM
authors.lastname: Harlan
authors.forename: Kristina I
authors.initials: KI
authors.lastname: Rother
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D000077270:Exenatide; D005215:Fasting / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage*; D019518:Postprandial Period / Q000187:drug effects; D014688:Venoms / Q000008:administration & dosage*
chemical_list: D001786:Blood Glucose; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms